.jpg)
Feb 24, 2019
Australian peanut therapy developer Aravax reveals positive Phase I trial results at AAAAI
February 25, 2019, Melbourne, Australia – Melbourne biotech to take its revolutionary peanut allergy treatment to Phase II clinical...
Feb 12, 2019
Aravax to Present PVX108 Phase 1 Clinical Trial Results at AAAAI 2019 Annual Meeting
February 13, 2019, MELBOURNE, Australia – Aravax, a clinical stage biotechnology company focused on developing the first safe and rapidly...